International Journal of Ophthalmology & Visual Science

| Peer-Reviewed |

Eplerenone in the Central Serous Chorioretinopathy Chronic

Received: May 21, 2020    Accepted: Jun. 02, 2020    Published: Jun. 17, 2020
Views:       Downloads:

Share This Article

Abstract

Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.

DOI 10.11648/j.ijovs.20200502.16
Published in International Journal of Ophthalmology & Visual Science ( Volume 5, Issue 2, June 2020 )
Page(s) 66-69
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Chronic Central Serous Chorioretinitis, Eplerenone, Sub-retinal Fluid, Mineralocorticoid Receptor

References
[1] Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.
Cite This Article
  • APA Style

    Mehdi Khamaily, Joumany Brahim Salem, Imane Tarib, Wafaa Akioud, Soukaina Haddougui, et al. (2020). Eplerenone in the Central Serous Chorioretinopathy Chronic. International Journal of Ophthalmology & Visual Science, 5(2), 66-69. https://doi.org/10.11648/j.ijovs.20200502.16

    Copy | Download

    ACS Style

    Mehdi Khamaily; Joumany Brahim Salem; Imane Tarib; Wafaa Akioud; Soukaina Haddougui, et al. Eplerenone in the Central Serous Chorioretinopathy Chronic. Int. J. Ophthalmol. Vis. Sci. 2020, 5(2), 66-69. doi: 10.11648/j.ijovs.20200502.16

    Copy | Download

    AMA Style

    Mehdi Khamaily, Joumany Brahim Salem, Imane Tarib, Wafaa Akioud, Soukaina Haddougui, et al. Eplerenone in the Central Serous Chorioretinopathy Chronic. Int J Ophthalmol Vis Sci. 2020;5(2):66-69. doi: 10.11648/j.ijovs.20200502.16

    Copy | Download

  • @article{10.11648/j.ijovs.20200502.16,
      author = {Mehdi Khamaily and Joumany Brahim Salem and Imane Tarib and Wafaa Akioud and Soukaina Haddougui and Yassine Mouzari and Fouad El Asri and Karim Reda and Abdelbarre Oubaaz},
      title = {Eplerenone in the Central Serous Chorioretinopathy Chronic},
      journal = {International Journal of Ophthalmology & Visual Science},
      volume = {5},
      number = {2},
      pages = {66-69},
      doi = {10.11648/j.ijovs.20200502.16},
      url = {https://doi.org/10.11648/j.ijovs.20200502.16},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ijovs.20200502.16},
      abstract = {Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.},
     year = {2020}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Eplerenone in the Central Serous Chorioretinopathy Chronic
    AU  - Mehdi Khamaily
    AU  - Joumany Brahim Salem
    AU  - Imane Tarib
    AU  - Wafaa Akioud
    AU  - Soukaina Haddougui
    AU  - Yassine Mouzari
    AU  - Fouad El Asri
    AU  - Karim Reda
    AU  - Abdelbarre Oubaaz
    Y1  - 2020/06/17
    PY  - 2020
    N1  - https://doi.org/10.11648/j.ijovs.20200502.16
    DO  - 10.11648/j.ijovs.20200502.16
    T2  - International Journal of Ophthalmology & Visual Science
    JF  - International Journal of Ophthalmology & Visual Science
    JO  - International Journal of Ophthalmology & Visual Science
    SP  - 66
    EP  - 69
    PB  - Science Publishing Group
    SN  - 2637-3858
    UR  - https://doi.org/10.11648/j.ijovs.20200502.16
    AB  - Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.
    VL  - 5
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

  • Section